BIOTECHNOLOGY-HEADER

RUS

      

ENG

Vol 37(2021) N 6 p. 74-83; DOI 10.21519/0234-2758-2021-37-6-74-83
E.S. Bobrov1, A.Yu. Gorbunova1, E.P. Sannikova1, I.I. Gubaidullin1,2, O.M. Ignatova1, M.Yu. Kopaeva1, N.V. Bulushova1, and D.G. Kozlov1*

Co-Purification of Recombinant Modified Glucagon-Like and Glucose-Dependent Insulinotropic Peptide to Create a Two-Component Drug for the Treatment of Type 2 Diabetes Mellitus and Obesity

1Kurchatov Institute National Research Center, Moscow, 123182, Russia
2NRC Kurchatov Institute-GOSNIIGENETIKA Kurchatov Genomic Center, Moscow, 117545, Russia

*Kozlov_DG@rrcki.ru
Received - 01.06.2021; Accepted - 08.09.2021

References

In addition to the previously developed recombinant modified human glucagon-like peptide 1 (rmglp1, Glypin), a recombinant modified human glucose-dependent insulinotropic peptide (RMGIP) has been obtained. A new universal reverse-phase HPLC technique has been proposed allowing quantitative analysis of rmGlp1 and rmGip separately and as part of a two-component preparation. The data show that the design of recombinant human rmGip according to the Glypine formula makes it possible to produce one-component and two-component preparations containing various rmGip and rmGlp1 protein ratios ranging from 1:0 to 20:1, using cell biomass samples mixed in predetermined proportions. Studies of human rmGip activity in a mouse model revealed reduced specific activity and signs of weak antagonistic effects. In this regard, there is a need for further study of human rmGip activity in a mouse model, including the use of alternative mouse or rat rmGip.

type 2 diabetes mellitus; two-component drug, glucose-dependent insulinotropic peptide, glucagon-like peptide-1

The work was supported by the Internal Grant from National Research Center Kurchatov Institute.



GOSNIIGENETIKA-FOOTER GOSNIIGENETIKA